MedPath

Comparing anti-hypertensive combination therapy of fixed dose losartan and hydrochlorothiazide(HCTZ) versus angiotensin receptor blocker(ARB) and calcium channel blocker(CCB) on hypertensive patients whose blood pressures don't lower enough,effect and influence of metabolic system trial.

Phase 4
Conditions
Hypertension
Registration Number
JPRN-UMIN000001692
Lead Sponsor
Hypertension and Metabolism Study group in East Saitama
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with uncontrolled diabetes (HbA1c more than 9.0%) 2) Patients with secondary hypertension 3)Patients who have stroke, AMI and/or other critical vascular complications that required hospitalization within 24 weeks prior to the intervention 4)Patients with liver dysfunction [GPT(ALT) over three times the normal value] 5)Patients with renal failure (serum creatinine more than 2.0 mg/dL) 6)Patients with uncontrolled hyperuricemia (more than 9.0mg/dL) 7)Patients with cardiac insufficiency (more than NYHA grade III) 8) Patients with severe malignant cancer or other unfavorable prognostic factors 9)Pregnant or possible pregnant women 10)Patients with a history of hypersensitivity to ingredients of losartan potassium or hydrochlorothiazide 11)Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 12)Patients who are considered not eligible for the study by the attending doctor due to medical reasons

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in blood pressure after 8 weeks. The achievement rate of the blood pressure target level(JSH criteria)after 8 weeks
Secondary Outcome Measures
NameTimeMethod
Inhibitory effect of development of diabetes. The rate of new-onset diabetes. Change in blood pressure,blood glucose,HbA1c,high-molecular weight adiponectin,hs-CRP,BNP,urinary microalbuminuria. Safty
© Copyright 2025. All Rights Reserved by MedPath